Chris Chen, WuXi Biologics CEO (Anthony Kwan/Bloomberg via Getty Images)

Hunt­ing for ‘cer­tain­ty and sta­bil­i­ty,’ WuXi Bio spot­lights client re­la­tion­ships

WuXi Bi­o­log­ics tout­ed its part­ner­ships and con­tracts in its an­nu­al re­port on Tues­day, not­ing that it has al­most 700 projects in its pipeline, which can help sup­ply the ser­vice provider with se­cu­ri­ty.

The stocks for both WuXi Bi­o­log­ics and its sis­ter com­pa­ny WuXi AppTec have yet to mean­ing­ful­ly re­cov­er since Jan­u­ary, when the draft of the BIOSE­CURE Act gained mo­men­tum. “In the face of un­cer­tain­ties, we are ded­i­cat­ed to find­ing cer­tain­ty and sta­bil­i­ty through our strate­gic ini­tia­tives,” CEO Chris Chen said in a press re­lease.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.